KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Targeting both ends of Hsp90: Chimeric N-terminal inhibitors and novobiocin-derivatized C-terminal inhibitors

    Thumbnail
    View/Open
    Shen_Gang_2007_6599173.pdf (1.586Mb)
    Issue Date
    2007-05-31
    Author
    Shen, Gang
    Publisher
    University of Kansas
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Medicinal Chemistry
    Rights
    This item is protected by copyright and unless otherwise specified the copyright of this thesis/dissertation is held by the author.
    Metadata
    Show full item record
    Abstract
    The 90 kDa heat shock proteins (Hsp90) are ubiquitously expressed in cells, which are integrally involved in the cell signaling, proliferation, and survival. Many proteins in tumor cells are dependent upon Hsp90 for their stability, refolding, and maturation. Additionally, inhibition of Hsp90 influences all six hallmarks of cancer: a documented feature unique to Hsp90. Thus, Hsp90 has emerged as one of the most promising targets for the treatment of cancer.

    Hsp90 is a homodimer, containing three domains. The N-terminal domain has an ATP-binding site that binds natural products geldanamcyin and radicicol. The middle domain is highly charged and has an affinity for co-chaperones and client proteins. The C-terminal domain is suspected to have an additional ATP-binding site that binds cisplatin and the natural product, novobiocin.

    Geldanamycin and radicicol are potent Hsp90 inhibitors. Co-crystal structures of these molecules bound to Hsp90, as well as other biological studies, provide evidence that the quinone moiety of geldanamycin and the resorcinol moiety of radicicol are key functional groups that contribute to their inhibitory activities. Therefore, it was reasonable to propose a seco-chimeric compound that contained both functional groups. Upon synthesis and biological evaluation of this lead compound, a series of related analogs were designed and synthesized. Preliminary data gave rise to structure-activity relationships that formed a great foundation for further investigation of this class of inhibitors. At the same time, biological investigations with macrocyclic chimeric compounds resulted in more potent inhibitors. Continued optimization of this class of inhibitors provides a guide for future studies.

    There are debates about why geldanamycin exhibits increased potency in cellular over in vitro assays. The co-crystal structure of geldanamycin bound to Hsp90 revealed that this compound adopts a cup-shaped conformation when the amide bond is isomerized from trans to cis. To improve the binding affinity for the chimeric inhibitors, a cis-amide functionality was incorporated. However, biological evaluations did not produce the expected results. It is believed that in hindsight, the cis-amide group does not allow the molecule to adopt the cup-shaped conformation.

    The aminocoumarin antibiotic, novobiocin, was reported to bind to the Hsp90 C-terminal ATP binding site. Structural modification of this compound led to an increase of 1000-fold in anti-proliferactive assays. This class of inhibitors can also induce degradation of Hsp90 client proteins. However, unlike the N-terminal ATP binding site, there is no reported co-crystal structure of Hsp90 C-terminus. Four photolabile novobiocin analogs were designed, synthesized, and incubated with Hsp90. Proteolytic studies indicated these compounds selectively bind to the same location as the natural product and are capable of labeling the protein. Additional studies are still ongoing.
    Description
    Dissertation (Ph.D.)--University of Kansas, Medicinal Chemistry, 2007.
    URI
    http://hdl.handle.net/1808/32101
    Collections
    • Dissertations [4466]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    Login

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps